Article
November Covenants Monthly: Altice, Lowell Add Pages to LME Playbook in Europe; What the Waldorf Appeal Could Mean for European LMEs; Kelvion’s 2032s Provoke Rare Investor Pushback
- Creditors find room for innovation in liability management excercises: Creditors continued to find creative avenues in LMEs, from Altice USA’s anti-cooperation maneuver to Lowell’s bond-to-securitization transaction.
- Waldorf Supreme Court appeal could prove pivotal for Part 26A: In what will be the first appeal on the Part 26A restructuring plan before the U.K. Supreme Court, market participants are hoping it will provide clarity and predictability amid a rising LME backdrop
- Transcom secures consent in coercive exchange offer: The offer incentivized early exchange while threatening a covenant-strip of existing notes to persuade holders of 2026s to roll into 2030s.
- Kelvion’s 2032s for leveraged buyout financing draws rare investor pushback: Amid a strong high- yield market in November, Kelvion stood out with a particularly aggressive covenant package – one that investors pushed back on.
Days later, Altice International announced a seismic drop-down of Altice Portugal and Altice Caribbean, which we estimate to be worth about 75% of the group’s revenue and 80% of the group’s adjusted EBITDA over the last 12 months. Altice International had scope for the move due to its estimated €12 billion investment capacity under its bond documentation. Further moves to deleverage the business may be upcoming, as the group announced intentions to sell its Israeli mobile business, Hot Mobile, for which Altice has nearly unrestricted ability to determine how to apply the proceeds.
While Lowell has indicated that the backstop providers hold sufficient majorities required to implement this, it is unlikely that Arini holds the requisite majorities to effect such a transaction via an amendment of the company’s debt or a scheme. In which event, a Selecta-style distressed disposal could be the best fallback option. Given that enforcement control shifts over time among the second lien, 1.5 lien and RCF lenders, Arini’s voting control or ability to refinance these tranches will be central to shaping the ultimate endgame.
Meanwhile, a new challenge to the Part 26A restructuring plan in the U.K. could have profound impacts on whether distressed creditors turn to courts to restructure debt or more cost-efficient, albeit acrimonious, methods like an LME.
At the center of the case is British oil and gas company Waldorf Production, which successfully received a leapfrog appeal to the U.K. Supreme Court (bypassing the Court of Appeal) seeking to overturn the High Court’s refusal to sanction its plan. The case marks the first time that a Part 26A restructuring plan appeal will be heard by the Supreme Court and some market participants are hoping that the case will bring increased clarity to the law. We evaluated how recent Court of Appeal decisions in Adler, Thames Water and Petrofac have muddied the water for those looking for predictability in the English Court, leading some to seek alternative methods, such as more aggressive LMEs, to manage debt.
Current shareholders have so far ruled out further equity injections, raising the possibility that a new investor could step in, though another option would be for the company to approach its bondholders. As previously reported, Arini has recently accumulated more than €100 million in Tele Columbus bonds, though sources stress that no creditor engagement has taken place to date.
To see a copy of our LME Risk In Brief relating to the Tele Columbus’ facility agreement dated March 19, 2024, email [email protected], together with a copy of the facility agreement.
To see our legal analyses on Tele Columbus AG’s €503.2 million term facilities maturing Jan. 1, 2029, (Term Loans) email us HERE with a copy of the March 19, 2024, amended and restated SFA. Find our legal analysis of the €636 million 10% senior secured PIK notes due 2029 HERE.
Meanwhile, Grifols successfully garnered enough support on its consent solicitation for holders of its 7.5% senior secured notes due 2030 to approve amendments which will align it more closely with terms set out in the more recently issued 7.125% senior secured notes due 2030. As we highlight in our analysis, though the amendments appear intended to facilitate the refinancing of its existing first lien credit facilities maturing in 2027 with first lien debt, the broad-brush approach of the amendments does leave open the possibility for any such refinancing debt being secured on a priming basis on non-collateral assets.

#

This flexibility was particularly high for priming debt, with structurally senior debt capacity at more than 4x the market average. This excessive capacity is driven largely by the absence of a non-guarantor debt cap and a blanket permission to secure all permitted debt on non-collateral. However, the notes contain a myriad of other weaknesses, including a second “Available Amount” builder basket, dividend-to-debt toggle, super-grower, and ‘ratio not worse’ test for making investments just to name a few.
Investors managed to carve back some added protection in a successful wave of pushback which saw cost savings and synergies capped, a limitation of super-growers to acquisitions and investments, as well as the addition of Chewy protection and partial J Crew protection. While the covenant package remains quite aggressive, falling from a score of 4.33 to 4.03, the presence of pushback is cause for cheer this holiday season. As we’ve highlighted previously, 2025 has so far been a relative dry spell for investor pushback, with only 9% of deals in Q1 – Q3 2025 drawing successful pushback compared to 19% in 2024. Given the unfolding LME landscape in Europe and high level of pushback seen in the loans market, despite typically tighter terms, we consider this a step in the right direction in the high-yield market.

To see our analyses of these documents, visit the Bonds Library HERE.



Amid ongoing underperformance and tightening liquidity, lenders to French pharmaceutical solutions and specialty chemicals producer Seqens have formed an ad hoc group. In this webinar on Nov 5., Octus’ Chetna Mistry, Robert Schach, and Jason Iheuko discussed the developing situation and analyzed the company’s options ahead of the expected balance sheet restructuring.
The webinar replay is available HERE.
This publication has been prepared by Octus, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2025 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.